Hu5F9-G4

DRUG4 trials

Sponsors

Gilead Sciences, Acerta Pharma BV, Hoffmann-La Roche

Conditions

Acute Myeloid LeukemiaDLBCLDiffuse Large B Cell LymphomaMyelodysplastic SyndromeNHLNon-hodgkin's LymphomaSolid Tumor

Phase 1

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

CompletedNCT02216409

Gilead SciencesSolid Tumor

Start: 2014-08-31End: 2018-12-31Updated: 2019-02-05

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

CompletedNCT02678338

Gilead SciencesAcute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2015-11-30End: 2019-02-28Updated: 2019-02-21

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

CompletedNCT03527147

Acerta Pharma BVDiffuse Large B Cell Lymphoma, DLBCL, NHL +1

Start: 2018-06-19End: 2021-03-31Updated: 2022-08-15

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

TerminatedNCT03922477

Hoffmann-La RocheAcute Myeloid Leukemia

Start: 2019-10-08End: 2020-11-03Updated: 2022-02-21

Related Papers

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Journal of Clinical Oncology2023-09-13108 citations

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Blood2022-11-155 citations

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood2021-11-052 citations

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Blood2019-11-136 citations

The effects of monoclonal anti‐CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia

Transfusion2019-06-10102 citations

A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.

Journal of Clinical Oncology2018-05-2013 citations

Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas.

Journal of Clinical Oncology2018-05-2010 citations

Abstract PR13: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies

Cancer Immunology Research2016-10-319 citations

A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers.

Journal of Clinical Oncology2016-05-2032 citations

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

PLoS ONE2015-09-21460 citations